We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DEVICE INDUSTRY LOOKS AT GPO REFORM, CMS GAINSHARING PROGRAM TO CUT DEVICE COSTS

DEVICE INDUSTRY LOOKS AT GPO REFORM, CMS GAINSHARING PROGRAM TO CUT DEVICE COSTS

June 19, 2006

Devicemakers are pushing for legislative reforms to rein in the administrative and other fees collected by group purchasing organizations (GPOs) that contribute to Medicare cost pressures, according to an industry expert.

GPOs, which facilitate device sales to hospitals, have reaped administrative profits that are adding to government costs, MDMA Executive Director Mark Leahy told attendees at the Medical Device Manufacturers Association (MDMA) meeting in Washington June 14.

"GPOs don't have to disclose how much money they take in or where it goes," Leahy said, noting that an audit of six GPOs showed they took in $2.3 billion in fees.

Leahy wants the government to look beyond devicemakers when it addresses the issue of cost effectiveness. The MDMA is seeking a repeal of the "safe harbor" that has allowed GPOs to tack on additional layers of administrative fees that can add nearly 10 percent to the cost hospitals pay for devices, Leahy said.

"This gets factored in to the price of products, which in turn affects Medicare reimbursement" for devicemakers, Leahy said, calling the current system a "perverse structure."

"GPOs are not returning all this money to hospitals but are instead redirecting it into their own profits," said Leahy. "Here you have the opportunity to enhance the quality of care and reduce the price." The MDMA wants Congress to look at GPO funding mechanisms. ()a href="http://www.fdanews.com/ddl/33_25/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing